A compound, composition and use thereof in the manufacture of a medicament for treating cardiac arrhythmias
A drug for treating arrhythmia was prepared by combining cassia anthraquinone, phloretin, and primrosein, which solved the problem of side effects of existing drugs and achieved a safer and more effective synergistic therapeutic effect.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-13
- Publication Date
- 2026-03-24
AI Technical Summary
Existing medications for arrhythmias have side effects, are not suitable for all populations, and lack safer and more effective treatment options.
Drugs for treating arrhythmia are prepared by using cassia anthraquinone, phloretin, and primrosein as active ingredients and combining them in different proportions. A preferred weight ratio of 5:2:1 is used to synergistically treat arrhythmia.
The combination of cassia anthraquinone, phloretin, and primrosein showed a significant synergistic effect in the treatment of arrhythmias, with better results than when used alone, providing a safer and more effective treatment option.
Smart Images
Figure BDA0004446785930000031
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, specifically to a compound, a composition, and its use in the preparation of a medicament for treating arrhythmias. Background Technology
[0002] Cardiac arrhythmia is an important cardiovascular disease; it can occur alone or in conjunction with other cardiovascular diseases; its prognosis is related to the etiology, precipitating factors, evolution trend, and whether it leads to severe hemodynamic disturbances. It can occur suddenly and cause sudden death, or it can continue to affect the heart and lead to its failure; if not treated in time, it poses a great risk.
[0003] Treatment methods for cardiac arrhythmias can be divided into non-pharmacological and pharmacological therapies; propafenone, propranolol, and verapamil are commonly used drugs for treating cardiac arrhythmias. However, existing drugs all have varying degrees of side effects and are not suitable for all populations. Therefore, developing more drugs for treating cardiac arrhythmias has significant application value. Summary of the Invention
[0004] In order to overcome at least one of the technical problems existing in the prior art, the present invention provides a compound, a composition and its use in the preparation of a medicament for treating arrhythmia.
[0005] The technical problem to be solved by the present invention is achieved through the following technical solution:
[0006] This invention provides the use of a compound in the preparation of a drug for treating arrhythmia, wherein the compound is cassia anthraquinone.
[0007] The inventors made a surprising discovery during their research: the compound cassia anthraquinone has a therapeutic effect on arrhythmias. Therefore, using cassia anthraquinone as an active ingredient to prepare drugs for treating arrhythmias has significant application value.
[0008] The present invention also provides the use of a compound in the preparation of a drug for treating arrhythmia, wherein the compound is phloretin.
[0009] The inventors made a surprising discovery during their research: the compound phlorizin has a therapeutic effect on arrhythmias. Therefore, using phlorizin as an active ingredient to prepare drugs for treating arrhythmias has significant application value.
[0010] The present invention also provides the use of a compound in the preparation of a drug for treating arrhythmia, wherein the compound is primoridin.
[0011] The inventors made a surprising discovery during their research: the compound primordin has a therapeutic effect on arrhythmias. Therefore, using primordin as an active ingredient to prepare drugs for treating arrhythmias has significant application value.
[0012] The present invention also provides a composition comprising any two or more of cassia anthraquinone, phloretin, and primordin.
[0013] Since compounds such as cassia anthraquinone, phloretin, and primordin have therapeutic effects on arrhythmias, a combination of any two or three of these compounds can also have therapeutic effects on arrhythmias.
[0014] Preferably, the composition comprises cassia anthraquinone, phloretin, and primordin.
[0015] More preferably, the weight ratio of cassia anthraquinone, phloretin, and primordin is 4–6:1–3:1–2.
[0016] Most preferably, the weight ratio of cassia anthraquinone, phloretin, and primordin is 5:2:1.
[0017] The inventors also surprisingly discovered in their research that the combination of cassia anthraquinone, phloretin, and primordin has a significantly higher therapeutic effect on arrhythmias than any single cassia anthraquinone, phloretin, or primordin alone. Furthermore, the combination of cassia anthraquinone, phloretin, and primordin exhibits a synergistic therapeutic effect on arrhythmias.
[0018] Furthermore, the inventors discovered in their research that the combination of any two of the three compounds—cassia anthraquinone, phloretin, and primordin—did not significantly enhance the therapeutic effect on arrhythmias compared to cassia anthraquinone, phloretin, or primordin alone. This indicates that combining any two of the three compounds does not produce a synergistic therapeutic effect on arrhythmias; only by combining all three compounds simultaneously can a synergistic therapeutic effect on arrhythmias be achieved.
[0019] The present invention also provides the use of the above composition in the preparation of a medicament for treating arrhythmias.
[0020] Preferably, the drug is in the form of granules, tablets, capsules, oral liquid, or injection.
[0021] Beneficial Effects: This invention provides a novel use for known compounds cassia anthraquinone, phlorizin, and primrosein. Studies have shown that compounds such as cassia anthraquinone, phlorizin, and primrosein have therapeutic effects on arrhythmias; therefore, using cassia anthraquinone, phlorizin, or primrosein, or combinations thereof, as active ingredients in the preparation of drugs for treating arrhythmias has significant application value. Detailed Implementation
[0022] The present invention will be further explained below with reference to specific embodiments, but the embodiments do not limit the present invention in any way.
[0023] Example 1: Experimental Test of Cardiac Arrhythmia
[0024] Ten-week-old Wistar rats were randomly divided into seven experimental groups and one blank control group, with 12 rats in each group, half male and half female. The experimental groups were administered the test sample (mixed with physiological saline) by gavage at a dose of 10 mg / kg / day. The blank control group was administered the same amount of physiological saline by gavage daily. After three consecutive days of gavage, the rats were anesthetized by intraperitoneal injection of 10% chloral hydrate one hour after the last administration. The external jugular vein was cannulated, and needle electrodes were inserted into the extremities. The electrocardiogram was recorded using the BL-420 biological function experimental system. After the electrocardiogram of the rats stabilized, aconitine was injected at a dose of 1 mg / kg through the external jugular vein cannulation site. The duration of arrhythmia in each group was recorded. The test results are shown in Table 1.
[0025] Among them, the sample administered by gavage to experimental group 1 was cassia anthraquinone; the sample administered by gavage to experimental group 2 was phloretin; the sample administered by gavage to experimental group 3 was primordin; the sample administered by gavage to experimental group 4 was a combination of cassia anthraquinone and phloretin in a weight ratio of 5:2; the sample administered by gavage to experimental group 5 was a combination of cassia anthraquinone and primordin in a weight ratio of 5:1; the sample administered by gavage to experimental group 6 was a combination of phloretin and primordin in a weight ratio of 2:1; and the sample administered by gavage to experimental group 7 was a combination of cassia anthraquinone, phloretin, and primordin in a weight ratio of 5:2:1.
[0026] Table 1. Experimental results of the treatment of cardiac arrhythmias with the compounds or compositions of the present invention
[0027]
[0028] As shown in Table 1, the duration of arrhythmia in rats in experimental groups 1-3 was significantly shorter than that in the blank control group. This indicates that the compounds cassia anthraquinone, phloretin, or primrosein have therapeutic effects on arrhythmia; therefore, using cassia anthraquinone, phloretin, and primrosein as active ingredients in the preparation of drugs for treating arrhythmia has significant application value.
[0029] As shown in Table 1, the duration of arrhythmia in rats in the experimental group (4-6) was significantly shorter than that in the blank control group. This indicates that the combination of any two of cassia anthraquinone, phloretin, and primrosein also has a therapeutic effect on arrhythmia. Therefore, using any two of cassia anthraquinone, phloretin, and primrosein as active ingredients in the preparation of drugs for treating arrhythmia has significant application value.
[0030] As shown in Table 1, the duration of arrhythmia in experimental group 7 was significantly shorter than that in experimental groups 1-3. This indicates that the combination of cassia anthraquinone, phlorizin, and primrosein has a significantly higher therapeutic effect on arrhythmia than any single compound. Furthermore, the combination of cassia anthraquinone, phlorizin, and primrosein can have a synergistic therapeutic effect on arrhythmia. However, the duration of arrhythmia in experimental groups 4-6 was not significantly reduced compared to experimental groups 1-3. This suggests that combining any two of these compounds does not produce a synergistic therapeutic effect on arrhythmia; only the simultaneous combination of all three compounds can achieve a synergistic therapeutic effect.
[0031] Example 2: Preparation of Granules
[0032] Granules were prepared using cassia anthraquinone as the active ingredient, following conventional formulation techniques in the field.
[0033] Example 3: Preparation of Granules
[0034] Using phloretin as the active ingredient, it is formulated into granules according to conventional formulation techniques in the field.
[0035] Example 4: Preparation of Granules
[0036] Using primordin as the active ingredient, it is formulated into granules according to conventional formulation techniques in this field.
[0037] Example 5: Preparation of Granules
[0038] A granule formulation was prepared using a composition of cassia anthraquinone and phloretin in a weight ratio of 5:2 as the active ingredient, following conventional formulation techniques in the art.
[0039] Example 6: Preparation of Granules
[0040] A granule formulation was prepared using a composition of cassia anthraquinone and primordin in a weight ratio of 5:1 as the active ingredient, following conventional formulation techniques in the art.
[0041] Example 7 Preparation of Granules
[0042] A granule formulation was prepared using a composition of phloretin and primordin in a weight ratio of 2:1 as the active ingredient, following conventional formulation techniques in the art.
[0043] Example 8: Preparation of Granules
[0044] A granule formulation was prepared using a composition of cassia anthraquinone, phloretin, and primordin in a weight ratio of 5:2:1 as the active ingredient, following conventional formulation techniques in the art.
[0045] Example 9: Preparation of Tablets
[0046] The tablets are prepared using cassia anthraquinone as the active ingredient and following conventional formulation techniques in the field.
[0047] Example 10: Preparation of Capsules
[0048] Using phloretin as the active ingredient, capsules are prepared according to conventional formulation techniques in the field.
[0049] Example 11 Preparation of oral liquid
[0050] Using primordin as the active ingredient, an oral liquid was prepared according to conventional formulation techniques in the field.
[0051] Example 12 Preparation of Injection
[0052] An injectable formulation is prepared using a composition of cassia anthraquinone, phloretin, and primordin in a weight ratio of 5:2:1 as the active ingredient, following conventional formulation techniques in the art.
Claims
1. The use of a compound in the preparation of a medicament for treating arrhythmias, characterized in that, The aforementioned The compound is primordin.
2. A composition, characterized in that, It contains anthraquinone, phloretin, and primordin.
3. The composition according to claim 2, characterized in that, The weight ratio of cassia anthraquinone, phloretin, and primordin is 4~6:1~3:1~2.
4. The composition according to claim 3, characterized in that, The weight ratio of cassia anthraquinone, phloretin, and primordin is 5:2:
1.
5. Use of the composition according to any one of claims 2 to 4 in the preparation of a medicament for treating arrhythmias.
6. The application according to claim 1 or 5, characterized in that, The drug is available in the form of granules, tablets, capsules, oral liquids, or injections.